首页> 美国卫生研究院文献>Molecular Medicine Reports >Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
【2h】

Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure

机译:一系列终末期肝病模型的预后性能以及相应的Δ得分在乙型肝炎急性慢性肝衰竭患者中的​​作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from antivirals. A total of 77 patients with ACHBLF of mean age 46 years, 82% male, with 58.4% receiving antivirals, were recruited for this study. The Δ scores for MELDs were defined as the changes one week after admission. Thirty-eight (49%) patients (22 treated with antivirals) died within three months. The mean MELD and ΔMELD scores of the survival group were 19.5±4.4 and 0.2±3.7 respectively, and those of the mortality group were 23.5±5.5 and 7.9±6, respectively. The area under the receiver operating characteristic curve (AUC) for MELD, integrated MELD (iMELD), MELD with the addition of serum sodium (MELD-Na), updated MELD (upMELD), MELD excluding the international normalized ratio (INR; MELD-XI), United Kingdom MELD (UKMELD) and their Δ scores were 0.72, 0.81, 0.77, 0.69, 0.65, 0.77 and 0.86, 0.83, 0.83, 0.82, 0.79 and 0.79, respectively. iMELD and MELD-Na significantly improved the accuracy of MELD (P<0.05). A cut-off value of 41.5 for the iMELD score can prognose 71% of mortalities with a specificity of 85%. In each pair of models, the Δ score was superior to its counterpart, particularly when applied to patients with MELD ≤30. Decreased accuracy was observed for all models in the subset of patients treated with antivirals, although their baseline characteristics were comparable to those of untreated patients, while iMELD, MELD-Na and respective Δ models remained superior with regard to the predictability. The iMELD and MELD-Na models predicted three-month mortality more accurately, while the Δ models were superior to their counterparts when MELD ≤30; however, their performance was altered by antivirals, and thus requires optimization.
机译:本研究旨在比较一系列急性乙型肝炎慢性乙肝衰竭(ACHBLF)的终末期肝病(MELD)模型和相应的德尔塔(Δ)评分评分系统的短期预后表现),并研究抗病毒药的潜在作用。这项研究共招募了77名平均年龄46岁的ACHBLF患者,其中男性占82%,接受抗病毒药物占58.4%。 MELD的Δ得分定义为入院后一周的变化。 38名患者(49%)(22名接受抗病毒药物治疗)在三个月内死亡。存活组的平均MELD和ΔMELD得分分别为19.5±4.4和0.2±3.7,而死亡率组的平均MELD和ΔMELD得分分别为23.5±5.5和7.9±6。 MELD的接收器工作特性曲线(AUC)下的面积,整合的MELD(iMELD),添加了血清钠的MELD(MELD-Na),更新的MELD(upMELD),MELD(不包括国际标准化比值(INR; MELD- XI),英国MELD(UKMELD)及其Δ得分分别为0.72、0.81、0.77、0.69、0.65、0.77和0.86、0.83、0.83、0.82、0.79和0.79。 iMELD和MELD-Na显着提高了MELD的准确性(P <0.05)。 iMELD评分的临界值为41.5,可以预知71%的死亡,特异性为85%。在每对模型中,尤其是当MELD≤30的患者应用时,Δ得分均优于其对应得分。尽管使用抗病毒药治疗的患者亚组的所有基线特征与未经治疗的患者相当,但所有模型的准确性均下降,而就可预测性而言,iMELD,MELD-Na和相应的Δ模型仍然较优。 iMELD和MELD-Na模型可以更准确地预测三个月的死亡率,而当MELD≤30时,Δ模型优于同类模型。但是,它们的性能已被抗病毒药物改变,因此需要进行优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号